Covidien to Acquire ev3 Inc. | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

Covidien to Acquire ev3 Inc.

June 2, 2010
by root
| Reprints

Global healthcare products provider Covidien (Dublin) has announced that they have signed a definitive merger agreement with Plymouth, Minn.-based ev3 Inc., under which Covidien will acquire all of the outstanding shares of ev3 Inc. for $22.50 per share in cash, for a total of $2.6 billion net of cash acquired.

The transaction is subject to customary closing conditions, and is expected to be completed by July 31, 2010. The Boards of Directors of both companies have unanimously approved the transaction.

Ev3 Inc. is a developer of peripheral vascular and neurovascular treatment technologies, including the primary interventional technologies used today: peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, flow diversion, thrombectomy catheters and occlusion balloons.

"With its broad product portfolio, clinical expertise and call-point synergies with our existing vascular franchise, ev3 will be an important addition to our innovative vascular intervention products,” said Richard J. Meelia, Chairman, President and CEO of Covidien.

The Health IT Summits gather 250+ healthcare leaders in cities across the U.S. to present important new insights, collaborate on ideas, and to have a little fun - Find a Summit Near You!


/news-item/covidien-acquire-ev3-inc

See more on

agario agario---betebet sohbet hattı betebet bahis siteleringsbahis